Abstract
1 Eight patients who failed or ceased to respond to levodopa, or who had developed the `on-off' phenomenon were treated additionally with nomifensine.
2 The dosage of nomifensine started at 50 mg, was increased to 150 mg daily, and other medication was continued unchanged. The duration of treatment was from 2-5 months. Assessments were carried out at 2-week intervals using a validated rating scale.
4 Loss of dopaminergic nigrostriatal neurones characterizes Parkinson's disease, and it is probably for this reason that indirect dopamine (DA) agonists, whose actions depend on intact presynaptic mechanisms, are less active.
3 Nomifensine was not shown to be of antiparkinsonian value in these patients but may be of value as an antidepressant in patients with Parkinson's disease.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Braestrup C., Scheel-Krüger J. Methylphenidate-like effects of the new antidepressant drug nomifensine (HOE 984). Eur J Pharmacol. 1976 Aug;38(2):305–312. doi: 10.1016/0014-2999(76)90333-2. [DOI] [PubMed] [Google Scholar]
- Costall B., Kelly D. M., Naylor R. J. Nomifensine: a potent dopaminergic agonist of antiparkinson potential. Psychopharmacologia. 1975;41(2):153–164. doi: 10.1007/BF00421073. [DOI] [PubMed] [Google Scholar]
- Gerhards H. J., Carenzi A., Costa E. Effect of nomifensine on motor activity, dopamine turnover rate and cyclic 3',5;-adenosine monophosphate concentrations of rat striatum. Naunyn Schmiedebergs Arch Pharmacol. 1974;286(1):49–63. doi: 10.1007/BF00499104. [DOI] [PubMed] [Google Scholar]
- Hoffmann I. 8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline, a new antidepressant. Arzneimittelforschung. 1973 Jan;23(1):45–50. [PubMed] [Google Scholar]
- Hunt P., Kannengiesser M., Raynaud J. Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum. J Pharm Pharmacol. 1974 May;26(5):370–371. doi: 10.1111/j.2042-7158.1974.tb09294.x. [DOI] [PubMed] [Google Scholar]
- Mindham R. H., Marsden C. D., Parkes J. D. Psychiatric symptoms during l-dopa therapy for Parkinson's disease and their relationship to physical disability. Psychol Med. 1976 Feb;6(1):23–33. doi: 10.1017/s0033291700007467. [DOI] [PubMed] [Google Scholar]
- Parkes J. D., Tarsy D., Marsden C. D., Bovill K. T., Phipps J. A., Rose P., Asselman P. Amphetamines in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1975 Mar;38(3):232–237. doi: 10.1136/jnnp.38.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pycock C., Milson J. A., Tarsy D., Marsden C. D. The effects of blocking catecholamine uptake on amphetamine-induced circling behaviour in mice with unilateral destruction of striatal dopaminergic nerve terminals. J Pharm Pharmacol. 1976 Jun;28(6):530–532. doi: 10.1111/j.2042-7158.1976.tb02785.x. [DOI] [PubMed] [Google Scholar]
- Sayers A. C., Handley S. L. A study of the role of catecholamines in the response to various central stimulants. Eur J Pharmacol. 1973 Jul;23(1):47–55. doi: 10.1016/0014-2999(73)90243-4. [DOI] [PubMed] [Google Scholar]
- Schacht U., Heptner W. Effect of nomifensine (HOE 984), a new antidepressant, on uptake of noradrenaline and serotonin and on release of noradrenaline in rat brain synaptosomes. Biochem Pharmacol. 1974 Dec 15;23(24):3413–3422. doi: 10.1016/0006-2952(74)90344-x. [DOI] [PubMed] [Google Scholar]
- Scheel-Krüger J. Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain. Eur J Pharmacol. 1971;14(1):47–59. doi: 10.1016/0014-2999(71)90121-x. [DOI] [PubMed] [Google Scholar]
- Teychenne P. F., Park D. M., Findley L. J., Rose F. C., Calne D. B. Nomifensine in parkinsonism. J Neurol Neurosurg Psychiatry. 1976 Dec;39(12):1219–1221. doi: 10.1136/jnnp.39.12.1219. [DOI] [PMC free article] [PubMed] [Google Scholar]